<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Cancer]]></title>
    <link>https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/therapeutic-areas/cancer</link>
    <description><![CDATA[Cancer]]></description>
    <pubDate>Fri, 26 Jun 2026 17:32:00 +0000</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update]]></title>
      <link>https://www.leadingmarketresearch.com/acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-drugs-in-dev</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drugs In Development, 2022, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.<br><br>Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.c <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-228298"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Mon, 26 Dec 2022 14:24:58 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Cancer Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update]]></title>
      <link>https://www.leadingmarketresearch.com/cancer-pain-drugs-in-development-by-stages-target-moa-roa-molecule-type</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Drugs In Development, 2022, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.<br><br>Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body&#039;s response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body&#039;s immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development,...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227802"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 21 Oct 2022 16:02:05 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031]]></title>
      <link>https://www.leadingmarketresearch.com/checkpoint-inhibitors-for-treating-cancer-market-report-2021-2031</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;">We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead....





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227627"><span class="price">$5,119.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 21 Oct 2022 14:50:56 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Urethral Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/urethral-cancer-drugs-in-development-by-stages-target-moa-roa-molecule</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Urethral Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Urethral Cancer pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Urethral Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/universit...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227353"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Penile Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/penile-cancer-drugs-in-development-by-stages-target-moa-roa-molecule-ty</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Penile Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Penile Cancer pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Penile Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university webs...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227363"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Laryngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/laryngeal-cancer-drugs-in-development-by-stages-target-moa-roa-molecule</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Laryngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Laryngeal Cancer pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Laryngeal Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/univer...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227365"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/t-cell-acute-lymphocytic-leukemia-t-cell-acute-lymphoblastic-leukaemia-dr</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter stra...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227371"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Chronic Myelomonocytic Leukemia (CMML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/chronic-myelomonocytic-leukemia-cmml-drugs-in-development-by-stages-targ</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Chronic Myelomonocytic Leukemia (CMML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Chronic Myelomonocytic Leukemia (CMML) pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Chronic Myelomonocytic Leukemia (CMML), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced fr...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227389"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[B-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/b-cell-leukemia-drugs-in-development-by-stages-target-moa-roa-molecule</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>B-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the B-Cell Leukemia pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/universit...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227393"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Natural Killer Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/natural-killer-cell-lymphomas-drugs-in-development-by-stages-target-moa</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Natural Killer Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Natural Killer Cell Lymphomas pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Natural Killer Cell Lymphomas, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227395"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Primary Mediastinal B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/primary-mediastinal-b-cell-lymphoma-drugs-in-development-by-stages-target</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Primary Mediastinal B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227405"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Marginal Zone B-cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/marginal-zone-b-cell-lymphoma-drugs-in-development-by-stages-target-moa</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Marginal Zone B-cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Marginal Zone B-cell Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227407"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-dr</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter stra...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227409"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 13:33:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Hemophagocytic Lymphohistiocytosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/hemophagocytic-lymphohistiocytosis-drugs-in-development-by-stages-target</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Hemophagocytic Lymphohistiocytosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Hemophagocytic Lymphohistiocytosis pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Hemophagocytic Lymphohistiocytosis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Ma...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227167"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 12:37:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Hormone Sensitive Breast Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/hormone-sensitive-breast-cancer-drugs-in-development-by-stages-target-moa</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Hormone Sensitive Breast Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Hormone Sensitive Breast Cancer pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Hormone Sensitive Breast Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Dir...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227181"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 12:37:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/lymphoblastic-lymphoma-drugs-in-development-by-stages-target-moa-roa-mo</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Lymphoblastic Lymphoma pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Lymphoblastic Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary databas...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227243"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 12:37:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/squamous-non-small-cell-lung-carcinoma-drugs-in-development-by-stages-targ</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Squamous Non-Small Cell Lung Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Squamous Non-Small Cell Lung Carcinoma pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Carcinoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced fr...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227247"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 12:37:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Testicular Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/testicular-cancer-drugs-in-development-by-stages-target-moa-roa-molecul</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Testicular Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Testicular Cancer pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Testicular Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/uni...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227249"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 12:37:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/splenic-marginal-zone-b-cell-lymphoma-drugs-in-development-by-stages-targe</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Splenic Marginal Zone B-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Splenic Marginal Zone B-Cell Lymphoma pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Splenic Marginal Zone B-Cell Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227287"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 12:37:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Primary CNS Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/primary-cns-lymphoma-drugs-in-development-by-stages-target-moa-roa-mole</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Primary CNS Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Primary CNS Lymphoma pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Primary CNS Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary databases, co...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227317"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 12:37:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/thrombopoietin-receptor-myeloproliferative-leukemia-protein-or-proto-oncog</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.<br><br>Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted therapeutics development and features dormant and discontinued projects.<br><...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227110"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 15:59:09 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Cutaneous T-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/cutaneous-t-cell-lymphoma-drugs-in-development-by-stages-target-moa-roa</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Cutaneous T-Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietar...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227113"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 15:59:09 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Interstitial Lung Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/interstitial-lung-fibrosis-drugs-in-development-by-stages-target-moa-roa</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Interstitial Lung Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Interstitial Lung Fibrosis pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprie...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226991"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 15:44:46 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-drugs-in-develop</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226720"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 14:45:37 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Muscle Invasive Bladder Cancer (MIBC) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/muscle-invasive-bladder-cancer-mibc-drugs-in-development-by-stages-targe</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Muscle Invasive Bladder Cancer (MIBC) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Muscle Invasive Bladder Cancer (MIBC) pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226738"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 14:45:37 +0000</pubDate>
    </item>
  </channel>
</rss>
